Get the Stockscreener App
23.91
1.31%
0.2648
Olema Pharmaceuticals Inc stock is traded at $23.91, with a volume of 689.51K.
It is up +1.31% in the last 24 hours and down -16.78% over the past month.
Olema Pharmaceuticals inc is a clinical-stage biopharmaceutical company. It is focused on the discovery, development, and commercialization of next generation targeted therapies for women's cancers. Its therapies offer the potential to improve outcomes for women living with cancer. The company has completed discovery and preclinical studies of OP-1250. OP-3136 is another drug candidate in the company's product pipeline.
See More
Previous Close:
$23.65
Open:
$23.85
24h Volume:
689.51K
Relative Volume:
0.19
Market Cap:
$1.92B
Revenue:
-
Net Income/Loss:
$-96.66M
P/E Ratio:
-11.12
EPS:
-2.15
Net Cash Flow:
$-83.73M
1W Performance:
-4.20%
1M Performance:
-16.78%
6M Performance:
+351.22%
1Y Performance:
+385.02%
1-Day Range:
$22.79
$24.18
1-Week Range:
$22.40
$26.48
52-Week Range:
$2.86
$36.26
Olema Pharmaceuticals Inc Stock (OLMA) Company Profile
Name
Olema Pharmaceuticals Inc
Sector
Industry
Phone
(415) 651-3316
Address
780 BRANNAN STREET, SAN FRANCISCO
Compare OLMA vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
OLMA
Olema Pharmaceuticals Inc
|
23.96 | 1.90B | 0 | -96.66M | -83.73M | -2.15 |
|
VRTX
Vertex Pharmaceuticals Inc
|
464.61 | 117.03B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
788.43 | 82.35B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
834.10 | 51.64B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
311.03 | 42.58B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
345.82 | 38.87B | 4.98B | 69.60M | 525.67M | 0.5198 |
Olema Pharmaceuticals Inc Stock (OLMA) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Feb-11-26 | Initiated | Stifel | Buy |
| Jan-07-26 | Initiated | Piper Sandler | Overweight |
| Oct-08-25 | Initiated | Guggenheim | Buy |
| Aug-12-25 | Reiterated | Citigroup | Buy |
| Apr-02-24 | Initiated | Goldman | Buy |
| Jan-30-24 | Initiated | Citigroup | Buy |
| Jul-21-23 | Initiated | Oppenheimer | Outperform |
| May-05-23 | Initiated | CapitalOne | Overweight |
| Feb-22-23 | Initiated | Credit Suisse | Outperform |
| Jul-06-22 | Resumed | Canaccord Genuity | Buy |
| Jun-09-22 | Upgrade | H.C. Wainwright | Neutral → Buy |
| Feb-28-22 | Initiated | H.C. Wainwright | Neutral |
| Dec-07-21 | Resumed | Cowen | Outperform |
| Dec-14-20 | Initiated | Canaccord Genuity | Buy |
| Dec-14-20 | Initiated | Cowen | Outperform |
| Dec-14-20 | Initiated | JP Morgan | Overweight |
| Dec-14-20 | Initiated | Jefferies | Buy |
View All
Olema Pharmaceuticals Inc Stock (OLMA) Latest News
This Olema Pharmaceuticals Analyst Begins Coverage On A Bullish Note; Here Are Top 4 Initiations For Wednesday - Benzinga
Stifel Initiates Coverage on Olema Pharmaceuticals (OLMA) with B - GuruFocus
Olema Pharmaceuticals (NASDAQ:OLMA) Now Covered by Analysts at Stifel Nicolaus - MarketBeat
Stifel Nicolaus Initiates Coverage on Olema Pharmaceuticals With Buy Rating - marketscreener.com
Candriam S.C.A. Increases Stock Position in Olema Pharmaceuticals, Inc. $OLMA - MarketBeat
Will Olema Pharmaceuticals Inc. stock benefit from automationJuly 2025 Closing Moves & Weekly High Return Stock Opportunities - mfd.ru
Stifel initiates Olema Pharmaceuticals stock with Buy rating, $48 target By Investing.com - Investing.com Canada
Olema Pharmaceuticals, Inc. Rings the Closing Bell - Nasdaq
Olema Oncology to Participate in Upcoming Investor Conferences - Sahm
Olema Pharmaceuticals seeks NDA lead for biotech program - Traders Union
Olema Pharmaceuticals, Inc. (NASDAQ:OLMA) Given Consensus Rating of "Moderate Buy" by Analysts - MarketBeat
Weekly Recap: Does Olema Pharmaceuticals Inc have pricing power2025 Key Highlights & High Conviction Trade Alerts - baoquankhu1.vn
Institutional Investors Control 63% of Olema Pharmaceuticals, Inc. (NASDAQ:OLMA) and Were Rewarded Last Week After Stock Increased 7.2% - 富途牛牛
Cancer index surges 72% as Terns, Olema lead gains - BioWorld MedTech
Investment Review: Is Olema Pharmaceuticals Inc stock trending bullishQuarterly Trade Summary & Consistent Return Strategy Ideas - baoquankhu1.vn
Olema Pharmaceuticals to Present at Upcoming Investor Conferences in February 2026 - Quiver Quantitative
Breast cancer drug developer Olema lines up three investor talks - Stock Titan
Risks Report: Whats next for Olema Pharmaceuticals Inc stockJuly 2025 Setups & Growth Focused Investment Plans - baoquankhu1.vn
Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Short Interest in Olema Pharmaceuticals, Inc. (NASDAQ:OLMA) Decreases By 12.5% - MarketBeat
Olema Pharmaceuticals (NASDAQ:OLMA) Shares Gap DownTime to Sell? - MarketBeat
A Look At Olema Pharmaceuticals (OLMA) Valuation After Renewed Buy Ratings And Phase 3 Breast Cancer Plans - Sahm
Breakout Zone: How much upside does Olema Pharmaceuticals Inc haveJuly 2025 Market Mood & Accurate Buy Signal Alerts - baoquankhu1.vn
Trend Recap: What are analysts price targets for Olema Pharmaceuticals IncEarnings Miss & Fast Moving Stock Watchlists - baoquankhu1.vn
Olema Oncology CFO Shane Kovacs to depart after six-year tenure By Investing.com - Investing.com India
Olema CFO Exit Puts Focus On Palazestrant Plans And Cash Discipline - Yahoo Finance
Olema Oncology CFO Shane Kovacs to depart after six-year tenure - Investing.com Australia
Olema Pharmaceuticals CFO Shane Kovacs departs, CEO assumes interim finance role By Investing.com - Investing.com Nigeria
Olema Pharmaceuticals CFO Shane Kovacs departs, CEO assumes interim finance role - Investing.com Nigeria
Olema Pharmaceuticals stock falls after CFO announces departure By Investing.com - Investing.com South Africa
Olema Pharmaceuticals stock falls after CFO announces departure - Investing.com
Olema Pharmaceuticals (OLMA) Executive Leadership Shift - GuruFocus
Olema Pharmaceuticals CFO Departs; CEO Assumes Interim Role - TipRanks
Olema Pharmaceuticals Chief Operating and Financial Officer Shane Kovacs Departs - marketscreener.com
Olema Oncology Announces Departure of Chief Operating and Financial Officer - The Manila Times
Olema (NASDAQ: OLMA) CFO exits with $621,283 package as CEO steps in - Stock Titan
Olema Oncology announces departure of chief operating and financial officer - marketscreener.com
Breast cancer-focused Olema sees financial officer depart, CEO steps in - stocktitan.net
LifeSci Capital Reiterates a Buy on Olema Pharmaceuticals (OLMA) - Finviz
10 Best Small-Cap Stocks Ready to Explode in 2026 - Insider Monkey
Olema Pharmaceuticals (OLMA) stock jumps 6% in a weak market — what to watch next - TechStock²
Olema Pharmaceuticals (NASDAQ:OLMA) Trading 7.7% HigherHere's What Happened - MarketBeat
Should I invest in Olema Pharmaceuticals Inc. before earningsGap Down & High Conviction Trade Alerts - mfd.ru
SEC Enforcement Action Targets Insider Trading in the Pharmaceutical Industry - akingump.com
Aug Outlook: Does Olema Pharmaceuticals Inc have pricing power2025 Geopolitical Influence & High Conviction Trade Alerts - baoquankhu1.vn
Apellis, Olema, Exicure, Immunovant, LivePerson Insider Shake-Up - TipRanks
Harmon Cyrus, director at Olema, sells $268,800 in stock By Investing.com - Investing.com UK
Olema Pharmaceuticals (NASDAQ:OLMA) Director Cyrus Harmon Sells 10,000 Shares - MarketBeat
Harmon Cyrus, director at Olema, sells $268,800 in stock - Investing.com
Olema Pharmaceuticals Inc Stock (OLMA) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.73%
2.45%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):